---
title: "Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma"
description: "FLORHAM PARK, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ:CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262917853.md"
published_at: "2025-10-27T13:37:57.000Z"
---

# Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

> FLORHAM PARK, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ:CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S.

FLORHAM PARK, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ:CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S.

### Related Stocks

- [CLRB.US - Cellectar Bioscience](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply | Cellectar BioSciences Inc. has partnered with Ionetix Corporation in a multi-year agreement to secure supplies of alpha- | [Link](https://longbridge.com/en/news/269868087.md) |
| Oppenheimer Remains a Hold on Cellectar Biosciences (CLRB) | Cellectar Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $15.20. | [Link](https://longbridge.com/en/news/259777975.md) |
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/en/news/275921122.md) |
| James Van Der Beek Warned of the 1 Telling Cancer Symptom He Had Months Before His Death: ‘I Had No Idea… ‘ | James Van Der Beek, known for his roles in Dawson’s Creek and Varsity Blues, passed away at 48 from colorectal cancer. H | [Link](https://longbridge.com/en/news/275956382.md) |
| ZAWYA-PRESSR: Burjeel Medical City launches Sarcoma & Bone Center to strengthen care for rare and complex cancers | Burjeel Cancer Institute has launched a specialized Sarcoma & Bone Center at Burjeel Medical City in Abu Dhabi, enhancin | [Link](https://longbridge.com/en/news/275995782.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.